Meftagesic-DS is generally used to provide supportive symptomatic relief across key therapeutic domains where symptoms related to physical discomfort, fever, and inflammation often converge. The active components are commonly used to help address symptoms related to physical discomfort and inflammatory or irritative states. It is applied across domains where short-term symptomatic assistance is needed, providing support that helps ease the overall symptom burden of distressing manifestations.

“The combination is used across therapeutic areas where addressing pain, inflammation, and high body temperature simultaneously is considered relevant.”

---

Easing the Triad of Pain, Fever, and Inflammation

This medicine is applied in clinical settings that involve acute or unstable symptom patterns, particularly when symptoms related to physical discomfort are combined with elevated body temperature or localized swelling. The supportive therapeutic benefit may assist with easing the symptom burden during periods of heightened symptoms. It is frequently applied in scenarios where additional management of discomfort is required during common infections or minor musculoskeletal aches.

---

Relief for Acute Localized and Cyclical Pain

It is commonly used for conditions involving episodic or fluctuating manifestations, notably helping to ease cyclical pain and discomfort associated with menstrual pain (dysmenorrhea). The medication is relevant in contexts marked by increased discomfort from specific, sudden events, such as short-term localized inflammatory states. It is considered relevant for symptom management in pediatric patients.

Quick Fact: Relief for Menstrual Symptoms

The medication is commonly used to help ease cyclical pain and discomfort associated with dysmenorrhea.

Regulatory References

1. NIH MedlinePlus overview of Mefenamic Acid

Eligibility Map: Official Regulatory Information

This medicine is a fixed-dose combination and its official regulatory eligibility profile is determined by the contraindications for its active ingredients: Mefenamic Acid (an NSAID) and Paracetamol (Acetaminophen).

Eligibility Classification	Populations/Conditions
Contraindicated (Must Not Use)	Known hypersensitivity to Mefenamic Acid, Paracetamol, aspirin, or other NSAIDs.
	History of asthma, hives, or allergic-type reactions after taking aspirin or other NSAIDs.
	Severe active liver disease or impairment; Severe renal impairment or pre-existing kidney disease.
	Active gastrointestinal ulceration or bleeding; chronic inflammation of the upper or lower GI tract.
	Patients in the setting of Coronary Artery Bypass Graft (CABG) surgery.
	Women in the Third Trimester of Pregnancy (generally ge 30 weeks gestation).
Restricted/Not Recommended	Children under 14 years of age (safety and efficacy generally not established).
	Nursing/Breastfeeding mothers.
	Patients with pre-existing mild-to-moderate renal or hepatic impairment, or uncontrolled hypertension.

Use is allowed primarily for adults and adolescents (generally ge 14 years of age) who do not possess any of the documented contraindications. The contraindications enforce strict exclusions to mitigate serious risks related to allergic reactions, gastrointestinal complications, cardiovascular risk, and organ toxicity.

Meftagesic-DS's interaction profile is derived from the officially documented patterns for its two components: Mefenamic Acid (NSAID) and Paracetamol (Acetaminophen). Regulatory restrictions mandate that co-administration with other acetaminophen-containing products or systemic NSAIDs is prohibited to avoid cumulative toxicity risks, including hepatotoxicity and severe gastrointestinal events.

Documented Interaction Patterns

• Additive Pharmacodynamic Effects: The Mefenamic Acid component may decrease the efficacy of antihypertensive agents (e.g., ACE Inhibitors, ARBs) and diuretics by reducing prostaglandin synthesis. Both active components increase the risk of bleeding when co-administered with Oral Anticoagulants (like Warfarin), necessitating careful monitoring.
• Exposure Alterations: Co-administration with Magnesium Hydroxide-containing antacids significantly increases the rate and extent of Mefenamic Acid absorption. Other agents, such as Probenecid and Cholestyramine, are documented to alter the clearance or absorption of Paracetamol.
• Substance and Population Risk: The label notes that consumption of three or more alcoholic drinks per day while taking the Paracetamol component is associated with an increased risk of severe liver damage. Furthermore, the risk of toxicity is heightened in certain populations; for instance, Severe Hepatic Impairment is an official contraindication, and dose adjustments are advised in cases of Severe Renal Impairment.

Mechanism of Action: Peripheral and Central Modulation

This medication works by combining Mefenamic Acid and Paracetamol, resulting in a combined mechanism that modulates both peripheral inflammatory signaling and central nociceptive activity. Mefenamic Acid acts peripherally to reduce signaling that causes local tissue sensitization, while Paracetamol modulates central pain pathways and the body's temperature regulation system in the brain.

---

Anti-Inflammatory Cascade via COX Inhibition

Mefenamic Acid functions primarily by reversibly inhibiting the Cyclooxygenase (COX) enzymes (COX-1 and COX-2) in peripheral tissues. This action inhibits the molecular cascade that converts arachidonic acid into pro-inflammatory mediators, such as prostaglandin E2 (PGE2) . This inhibition reduces localized tissue swelling and heat and dampens the excitability of peripheral pain receptors (nociceptors), which contributes to the drug's mechanism of anti-inflammation and peripheral reduction of nociception.

---

Modulating Central Pain and Fever Signaling

Paracetamol exerts its effect mainly within the Central Nervous System (CNS), where it selectively modulates cyclooxygenase-like activity, resulting in reduced prostaglandin synthesis in the hypothalamus, the brain’s thermoregulatory center. This process facilitates the reset of an elevated body temperature set-point, resulting in the adjustment of body temperature downward. Additionally, Paracetamol modulates descending pain-suppressing pathways, which results in the central elevation of the pain threshold via a distinct nociceptive mechanism.

Official Administration Guidelines for Meftagesic-DS

Meftagesic-DS (Double Strength) is typically supplied as an oral suspension and must be used strictly according to prescribing information, which details the procedures for proper administration.

Instruction Category	Administration Guideline
Route of Administration	Oral (by mouth).
Preparation Requirements	The suspension bottle must be shaken well before each dose is measured.
Dosing Schedule	The dose must be accurately measured using a calibrated measuring device (such as the cup, syringe, or dropper provided) to ensure the precise volume is administered. Dosage is determined by the patient's age and body weight.
Timing in Relation to Meals	The medication should be administered with or immediately after food to mitigate potential gastrointestinal discomfort.
Frequency Pattern	Typically prescribed to be taken 2 to 3 times a day, maintaining the prescribed interval (e.g., every six hours).
Age-Group Rules	The medication is not recommended for children under 6 months of age. Dosage adjustments may be necessary for elderly patients or those with existing hepatic or renal impairment.
Missed Dose Rule	If a dose is missed, it should be taken as soon as it is remembered, unless it is nearly time for the next scheduled dose. Do not take a double dose to compensate for the missed one.

Connection to the Overall Use Protocol

General administration protocols mandate the use of the lowest effective dose for the shortest possible duration. The protocol establishes the sequence of shaking, measuring, and administering the oral suspension accurately, specifically tying the administration to food intake to meet safety requirements and prevent exceeding the maximum daily limits. Adherence to the prescribed age- and weight-based dose is mandatory.

Research evidence / Overview of studies for Meftagesic-DS

The evidence base involves research that was studied for various outcomes related to physical discomfort and temporary physiological imbalance, such as fever. The findings describe group patterns observed in the studies and should not be taken as individual predictions.

---

Evidence for Use in Primary Dysmenorrhea (Menstrual Pain)

Research exploring how symptoms change over time in conditions characterized by fluctuating or episodic manifestations, such as primary dysmenorrhea, primarily involves studies examining the medicine's Mefenamic Acid component. The evidence base includes Randomized Controlled Trials (RCTs) and systematic reviews.

What remains uncertain is the specific profile of the fixed-dose combination. Few high-powered trials have been published that directly compare the measured effects of the combination against those of the single active agents (Mefenamic Acid or Paracetamol alone) in this specific population. Follow-up durations were limited, typically evaluating effects across one to a few menstrual cycles.

---

Evidence for Use in Acute Pain and Fever Management

Research has explored how the combination of the active ingredients was evaluated in research contexts involving fluctuating or unstable symptoms. This includes RCTs and comparative trials was observed in various acute pain models, such as pain following dental procedures or minor soft-tissue injuries. Populations in these studies included both adults and children.

Research examined outcomes describing episodic or acute changes, such as analgesic efficacy endpoints and the documented time to onset of relief. Similarly, studies focusing on antipyresis monitored outcomes linked to inflammatory or irritative states by measuring the reduction in body temperature.

---

What Research Gaps and Uncertainties Remain

Research highlights what is known — and what is still uncertain — in the evidence landscape for Meftagesic-DS. The main limitations stem from the reliance on existing research for the single agents, meaning comparative evidence is lacking for the specific combination in many clinical settings.

Data for certain groups remain insufficient. Research exploring outcomes in older adults or populations with specific comorbidities is often limited. Also, long-term effects are not fully established, as the available evidence provides limited information for long-term outcomes or durability of effect. The research is ongoing in certain areas.

Key Studies & References

1. Evaluation of Efficacy and Tolerability of Acetaminophen (Paracetamol) and Mefenamic Acid and Paracetamol Combination as Antipyretic in Pediatric Patients with Febrile Illness
2. Oral Analgesics for Acute Dental Pain (Inclusion of combination therapy rationale)

Common questions about Meftagesic-DS (FAQ)

---

Q: How quickly can someone generally expect Meftagesic-DS to start working?

Official pharmacokinetic data indicates that the Paracetamol component is absorbed relatively quickly, with the highest concentration in the bloodstream typically reached about 10 to 60 minutes after taking an oral dose. The Mefenamic Acid component reaches its highest concentrations slightly slower, generally taking about 2 to 4 hours. The overall effect is influenced by the absorption rates of both active components.

---

Q: How long does the effect of one dose of Meftagesic-DS typically last?

The duration of the pain-relieving and fever-reducing effects is linked to the elimination half-lives of the active ingredients in the body. The elimination half-life for Paracetamol is about 1 to 3 hours, and for Mefenamic Acid, it is reported to be about 2 to 4 hours. This data provides context for the drug's duration of action.

---

Q: Does Meftagesic-DS commonly cause drowsiness or affect alertness?

Official labeling for the Mefenamic Acid component lists dizziness as a known side effect, which is an effect on the central nervous system (CNS). The presence of dizziness may be a consideration when performing tasks that require concentration. Drowsiness itself is not typically listed as a common side effect of the Mefenamic Acid component.

---

Q: Is there a maximum number of days Meftagesic-DS can be used continuously?

Regulatory guidance often specifies that for acute pain relief, continuous therapy for the Mefenamic Acid component should usually not exceed one week. For its use in primary dysmenorrhea (menstrual pain), the duration is typically limited to 2 to 3 days. Regulatory protocols emphasize the use of the lowest effective dose for the shortest duration possible.

---

Q: What official sources say about Meftagesic-DS use while breastfeeding?

Both active components of the medicine pass into breast milk. Due to the possibility of adverse effects, official safety advice generally describes the use of the medicine as potentially unsafe during breastfeeding. The medicine is restricted or not recommended during this time.

---

Q: Can individuals with high blood pressure use Meftagesic-DS?

Official labeling indicates that the medicine should be used cautiously in individuals with high blood pressure. Regulatory documents note that the NSAID component (Mefenamic Acid) can potentially lead to the onset of new high blood pressure or worsen existing hypertension. Because of this, the medicine is typically restricted or not recommended for patients with uncontrolled hypertension.

---

Q: Does Meftagesic-DS cause fluid retention or swelling?

Yes, official warnings state that the NSAID component, Mefenamic Acid, can cause fluid retention and swelling (edema). This may appear as swelling of the hands, feet, ankles, or lower legs. This effect is a documented risk associated with NSAID medicines.

---

Q: Is Meftagesic-DS the same as regular Meftagesic, or is it stronger?

The 'DS' designation typically stands for 'Double Strength'. This means the specific formulation contains a higher concentration or quantity of the active ingredients, Mefenamic Acid and Paracetamol, compared to the standard formulation of the product. This indicates a higher quantity of active ingredients in each dose.

---

Q: What is the difference between Meftagesic-DS and common pain relievers like ibuprofen?

Ibuprofen is a single-ingredient non-steroidal anti-inflammatory drug (NSAID). Meftagesic-DS is a fixed-dose combination medicine that includes an NSAID (Mefenamic Acid) and an analgesic and antipyretic agent (Paracetamol). It is designed to target pain, inflammation, and fever through the combined action of two distinct pharmacological classes.

---

Q: Can Meftagesic-DS be used for a general headache or migraine?

Regulatory documents for the combination often list headache as an indication for mild-to-moderate pain. Some research has also explored the use of the Mefenamic Acid component in the treatment of migraine. Indications are determined by official regulatory review.

---

Q: Can Meftagesic-DS affect the results of any lab tests?

Official safety advice states that if the medicine is taken for long-term treatment, a doctor may regularly monitor the patient's kidney function, liver function, and the levels of blood components. These tests may be affected by the drug components, requiring ongoing monitoring to ensure safety.

---

Q: What are the signs of taking too much Meftagesic-DS?

Symptoms of overdose for the components may include extreme tiredness, nausea, vomiting, stomach pain, black or tarry stools, and slowed breathing. Due to the Paracetamol component, there is a specific risk of severe liver damage (hepatotoxicity) if the maximum dose is exceeded. If an overdose is suspected, it is critical to seek medical help immediately.

---

Q: Is Meftagesic-DS a narcotic or habit-forming medicine?

No. Meftagesic-DS contains Mefenamic Acid (an NSAID) and Paracetamol (an analgesic/antipyretic). These components are not classified as narcotics and are not associated with problems of addiction, dependence, tolerance, or withdrawal, as they do not work on the opioid receptors in the brain.

---

Q: Why is this medication called 'DS'?

The abbreviation 'DS' is a designation used in the product name to mean 'Double Strength'. This indicates that the concentration or total dose of the active ingredients within the medicine is higher than that found in the standard formulation of the product.

---

Q: Is Meftagesic-DS available over the counter or does it require a prescription?

The regulatory status of this combination medicine varies by region. The product is considered a prescription-only medicine (POM) in many areas, but certain lower-dose or single-agent formulations may be available over the counter in some countries. Its status is governed by local regulatory laws.

---

Q: Are there any long-term use concerns with Meftagesic-DS noted in official documents?

Yes, regulatory documents carry warnings that the risk of serious side effects may increase with the duration of use. These risks include serious cardiovascular thrombotic events (like heart attack or stroke) and serious gastrointestinal events (like bleeding and ulceration). Therefore, the lowest effective dose for the shortest duration is mandated for use.

---

Q: Does Meftagesic-DS interact with herbal supplements?

Regulatory information for the individual components generally advises patients to inform their healthcare provider about all prescription or over-the-counter medicines, vitamins, minerals, and herbal remedies they are using. This is because interactions between drug components and supplements have not been tested in the same way as pharmacy medicines.

---

Q: Can Meftagesic-DS be used for post-operative pain relief?

Official guidance for the NSAID component (Mefenamic Acid) notes that NSAIDs may be a valuable option for post-operative pain relief in appropriate patients. However, its use is restricted for pain management immediately following coronary artery bypass graft (CABG) surgery, which is a contraindication.

---

Q: How does Meftagesic-DS compare to NSAIDs like naproxen, in terms of its class?

Naproxen is classified as a single-agent NSAID. Meftagesic-DS is unique because it is a fixed-dose combination medicine that combines an NSAID (Mefenamic Acid) with a distinct analgesic and antipyretic agent (Paracetamol). This places it in a different pharmacological class than single-agent NSAIDs.

---

Q: Is Meftagesic-DS used for dental pain?

Yes, regulatory documents for the combination often list toothache as an an indication for the management of mild-to-moderate pain. The NSAID component, Mefenamic Acid, is widely recognized in clinical use for managing various types of dental pain.

---

Q: Does Meftagesic-DS have an effect on fertility or conception?

Official prescribing information advises that Mefenamic Acid may temporarily interfere with ovulation and notes caution if a patient is planning to become pregnant. This is a factor to consider for women who are having difficulty conceiving.

---

Q: Why is it important to check the ingredients of other medicines when taking Meftagesic-DS?

It is important to check the ingredients of other medicines to avoid consuming additional products that contain Paracetamol (Acetaminophen) or a different NSAID. Taking multiple products with these components could lead to the unintended consumption of too high a dose of either agent, which increases the risk of toxicity, especially liver damage.

---

Q: Are there different brand names for the same ingredients found in Meftagesic-DS?

Yes, Paracetamol (Acetaminophen) is sold under a large number of different brand names globally. Additionally, other combination products containing both Mefenamic Acid and Paracetamol may exist under different brand names in various markets, depending on the manufacturer and the country.

---

Q: Can Meftagesic-DS be taken with certain vitamins or minerals?

Regulatory summaries generally advise patients to inform their healthcare provider about all prescription or over-the-counter medicines, as well as any vitamins or minerals they are using. This is a general caution to help ensure there are no unknown or unintended interactions between the drug's components and the supplements.

---

Q: Is the effect of Meftagesic-DS influenced by body weight?

Yes, for some patient groups, especially children, the accurate dosage is typically determined by body weight. Official pharmacokinetic studies have also examined how body weight may influence the distribution and clearance of the Paracetamol component, which can impact the medicine's effect.

---

Q: Are there specific instructions for disposing of unused Meftagesic-DS?

Official guidance recommends using community drug take-back programs or mail-back envelopes first. If these options are not available, it advises mixing the medicine with an undesirable substance (like dirt or used coffee grounds), placing the mixture in a sealed container, and discarding it in the household trash as part of a safe disposal process.

The storage and disposal of Meftagesic-DS (Mefenamic Acid and Paracetamol suspension) must adhere strictly to the conditions specified in official product labeling.

Storage Requirements

Condition	Official Regulatory Statement
Temperature	Store at a temperature below 30 C or at controlled room temperature [1.1, 2.1].
Protection	Keep in a cool and dry place, protected from light and moisture [2.3, 2.5].
Packaging	Store in the original container and ensure the container is kept tightly closed [1.1, 2.6].
Child Safety	Must be stored out of the sight and reach of children and pets [1.2, 2.2].

Disposal Instructions

All unused or expired medicine must be disposed of according to the instructions provided on the package or label [1.1, 2.6]. This ensures the medicine is not consumed by pets, children, or other people. The official guidance does not typically specify flushing; follow instructions to avoid environmental harm, such as using community drug take-back programs where available [3.1, 3.6].